ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years
Yalan Lei
Matched on ORCID iD 0000-0002-6953-6386; OpenAlex author ID A5073671015. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2024: 3 papers · 2025: 1 paper
Papers 4
- TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic lethality. Co-author DOI 10.1136/gutjnl-2024-332782↗
- Pirfenidone alleviates fibrosis by acting on tumour-stroma interplay in pancreatic cancer. Co-author DOI 10.1038/s41416-024-02631-9↗
- NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced autophagy. Co-author DOI 10.1038/s41419-024-06984-0↗
- PP2A complex disruptor SET prompts widespread hypertranscription of growth-essential genes in the pancreatic cancer cells. Co-author DOI 10.1126/sciadv.adk6633↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Mingming Xiao · 4 shared papers, 2024–2025 · strength 0.87
- Paper PP2A complex disruptor SET prompts widespread hypertranscription of growth-essential genes in the pancreatic cancer cel… DOI 10.1126/sciadv.adk6633↗
- Paper Pirfenidone alleviates fibrosis by acting on tumour-stroma interplay in pancreatic cancer. DOI 10.1038/s41416-024-02631-9↗
- Paper NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced auto… DOI 10.1038/s41419-024-06984-0↗
- Si Shi · 4 shared papers, 2024–2025 · strength 0.87
- Paper PP2A complex disruptor SET prompts widespread hypertranscription of growth-essential genes in the pancreatic cancer cel… DOI 10.1126/sciadv.adk6633↗
- Paper Pirfenidone alleviates fibrosis by acting on tumour-stroma interplay in pancreatic cancer. DOI 10.1038/s41416-024-02631-9↗
- Paper NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced auto… DOI 10.1038/s41419-024-06984-0↗
- Xianjun Yu · 3 shared papers, 2024–2025 · strength 0.66
- Paper PP2A complex disruptor SET prompts widespread hypertranscription of growth-essential genes in the pancreatic cancer cel… DOI 10.1126/sciadv.adk6633↗
- Paper Pirfenidone alleviates fibrosis by acting on tumour-stroma interplay in pancreatic cancer. DOI 10.1038/s41416-024-02631-9↗
- Paper TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic leth… DOI 10.1136/gutjnl-2024-332782↗
- Xiaoqi Mao · 2 shared papers, 2024 · strength 0.42
- Xuhui Tong · 2 shared papers, 2024–2025 · strength 0.42
- Paper NLRP4 renders pancreatic cancer resistant to olaparib through promotion of the DNA damage response and ROS-induced auto… DOI 10.1038/s41419-024-06984-0↗
- Paper TPX2 serves as a novel target for expanding the utility of PARPi in pancreatic cancer through conferring synthetic leth… DOI 10.1136/gutjnl-2024-332782↗
- Jin Xu · 2 shared papers, 2024–2025 · strength 0.42
- Xu He · 1 shared paper, 2024 · strength 0.24
- Di Wu · 1 shared paper, 2024 · strength 0.24
- Di Wu · 1 shared paper, 2024 · strength 0.21
- Xianjun Yu · 1 shared paper, 2024 · strength 0.21
- Mingwei Dong · 1 shared paper, 2024 · strength 0.21
- Jing Yang · 1 shared paper, 2024 · strength 0.21
- H. J. Yang · 1 shared paper, 2024 · strength 0.21
- Zhilong Ma · 1 shared paper, 2025 · strength 0.21
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.